Cargando…

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases

PURPOSE: This study investigated the relationship between BRAFV600E mutation of the primary tumor and radioiodine avidity in lung metastases (LMs) and then further evaluated the impact of BRAFV600E mutation and radioiodine avidity status on the prognosis of papillary thyroid cancer (PTC) with LMs. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shuhui, Qi, Mengfang, Tian, Tian, Dai, Hongyuan, Tang, Yuan, Huang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666419/
https://www.ncbi.nlm.nih.gov/pubmed/36407316
http://dx.doi.org/10.3389/fendo.2022.959089
_version_ 1784831500197298176
author Huang, Shuhui
Qi, Mengfang
Tian, Tian
Dai, Hongyuan
Tang, Yuan
Huang, Rui
author_facet Huang, Shuhui
Qi, Mengfang
Tian, Tian
Dai, Hongyuan
Tang, Yuan
Huang, Rui
author_sort Huang, Shuhui
collection PubMed
description PURPOSE: This study investigated the relationship between BRAFV600E mutation of the primary tumor and radioiodine avidity in lung metastases (LMs) and then further evaluated the impact of BRAFV600E mutation and radioiodine avidity status on the prognosis of papillary thyroid cancer (PTC) with LMs. METHODS: Ninety-four PTC patients with LMs after total thyroidectomy and cervical lymph node dissection between January 2012 and September 2021 were retrospectively included. All patients received BRAFV600E mutation examination of primary tumors and radioactive iodine (RAI) therapy. The therapeutic response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) assessments (version 1.1). For patients with target lesions, the response was divided into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD); for patients without target lesions, the response was divided into CR, non-CR/non-PD, and PD. In therapeutic response, PR and SD were classified as non-CR/non-PD for analysis. The chi-square test and logistic regression were used to analyze the impact factor on PD and mortality. Progression-free survival (PFS) and overall survival (OS) curves were constructed by the Kaplan–Meier method. RESULTS: It was found that 21.2% (7/33) of patients with positive BRAFV600E mutation and 62.3% (38/61) of patients with negative BRAFV600E mutation had radioiodine-avid LMs (χ(2) = 14.484, p = 0.000). Patients with positive BRAFV600E mutation are more likely to lose radioiodine avidity; the odds ratios (ORs) were 5.323 (95% CI: 1.953–14.514, p = 0.001). Finally, 25 patients had PD, and six patients died; loss of radioiodine avidity was the independent predictor for PD, and the ORs were 10.207 (95% CI: 2.629–39.643, p = 0.001); BRAFV600E mutation status was not correlated with PD (p = 0.602), whether in the radioiodine avidity group (p = 1.000) or the non-radioiodine avidity group (p = 0.867). Similarly, BRAFV600E mutation status was not correlated with mortality; only loss of radioiodine avidity was the unfavorable factor associated with mortality in univariate analyses (p = 0.030). CONCLUSION: Patients with LMs of PTC were more likely to lose radioiodine avidity when their primary tumor had positive BRAFV600E mutation; however, only radioiodine avidity and not BRAFV600E mutation status affected the clinical outcome of patients with lung metastatic PTC.
format Online
Article
Text
id pubmed-9666419
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96664192022-11-17 Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases Huang, Shuhui Qi, Mengfang Tian, Tian Dai, Hongyuan Tang, Yuan Huang, Rui Front Endocrinol (Lausanne) Endocrinology PURPOSE: This study investigated the relationship between BRAFV600E mutation of the primary tumor and radioiodine avidity in lung metastases (LMs) and then further evaluated the impact of BRAFV600E mutation and radioiodine avidity status on the prognosis of papillary thyroid cancer (PTC) with LMs. METHODS: Ninety-four PTC patients with LMs after total thyroidectomy and cervical lymph node dissection between January 2012 and September 2021 were retrospectively included. All patients received BRAFV600E mutation examination of primary tumors and radioactive iodine (RAI) therapy. The therapeutic response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) assessments (version 1.1). For patients with target lesions, the response was divided into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD); for patients without target lesions, the response was divided into CR, non-CR/non-PD, and PD. In therapeutic response, PR and SD were classified as non-CR/non-PD for analysis. The chi-square test and logistic regression were used to analyze the impact factor on PD and mortality. Progression-free survival (PFS) and overall survival (OS) curves were constructed by the Kaplan–Meier method. RESULTS: It was found that 21.2% (7/33) of patients with positive BRAFV600E mutation and 62.3% (38/61) of patients with negative BRAFV600E mutation had radioiodine-avid LMs (χ(2) = 14.484, p = 0.000). Patients with positive BRAFV600E mutation are more likely to lose radioiodine avidity; the odds ratios (ORs) were 5.323 (95% CI: 1.953–14.514, p = 0.001). Finally, 25 patients had PD, and six patients died; loss of radioiodine avidity was the independent predictor for PD, and the ORs were 10.207 (95% CI: 2.629–39.643, p = 0.001); BRAFV600E mutation status was not correlated with PD (p = 0.602), whether in the radioiodine avidity group (p = 1.000) or the non-radioiodine avidity group (p = 0.867). Similarly, BRAFV600E mutation status was not correlated with mortality; only loss of radioiodine avidity was the unfavorable factor associated with mortality in univariate analyses (p = 0.030). CONCLUSION: Patients with LMs of PTC were more likely to lose radioiodine avidity when their primary tumor had positive BRAFV600E mutation; however, only radioiodine avidity and not BRAFV600E mutation status affected the clinical outcome of patients with lung metastatic PTC. Frontiers Media S.A. 2022-11-02 /pmc/articles/PMC9666419/ /pubmed/36407316 http://dx.doi.org/10.3389/fendo.2022.959089 Text en Copyright © 2022 Huang, Qi, Tian, Dai, Tang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Huang, Shuhui
Qi, Mengfang
Tian, Tian
Dai, Hongyuan
Tang, Yuan
Huang, Rui
Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
title Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
title_full Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
title_fullStr Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
title_full_unstemmed Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
title_short Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
title_sort positive brafv600e mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666419/
https://www.ncbi.nlm.nih.gov/pubmed/36407316
http://dx.doi.org/10.3389/fendo.2022.959089
work_keys_str_mv AT huangshuhui positivebrafv600emutationofprimarytumorinfluencesradioiodineaviditybutnotprognosisofpapillarythyroidcancerwithlungmetastases
AT qimengfang positivebrafv600emutationofprimarytumorinfluencesradioiodineaviditybutnotprognosisofpapillarythyroidcancerwithlungmetastases
AT tiantian positivebrafv600emutationofprimarytumorinfluencesradioiodineaviditybutnotprognosisofpapillarythyroidcancerwithlungmetastases
AT daihongyuan positivebrafv600emutationofprimarytumorinfluencesradioiodineaviditybutnotprognosisofpapillarythyroidcancerwithlungmetastases
AT tangyuan positivebrafv600emutationofprimarytumorinfluencesradioiodineaviditybutnotprognosisofpapillarythyroidcancerwithlungmetastases
AT huangrui positivebrafv600emutationofprimarytumorinfluencesradioiodineaviditybutnotprognosisofpapillarythyroidcancerwithlungmetastases